Journal Club: Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals

January 2026

In this journal club review, clinical pharmacist Danielle Gatti Palumbo, breaks down a March 2025 study examining how guselkumab’s unique Fc-domain interactions with CD64-positive, IL-23–producing myeloid cells enhance its potency in neutralizing IL-23 signaling. The discussion explores the immunologic role of IL-23 in inflammatory diseases such as psoriasis, psoriatic arthritis, and inflammatory bowel disease, compares Fc-domain differences between IL-23 inhibitors, and highlights key in vitro findings using flow cytometry, live-cell imaging, and co-culture assays. This concise overview helps APPs and clinicians better understand emerging mechanisms that may influence therapeutic efficacy and treatment selection in IL-23–driven inflammatory conditions.